Stockholders' equity (Tables) |
12 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mar. 31, 2025 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Stockholders' equity [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Derivative Warrant Liabilities Measured at Fair Value and Reconciliation of Changes in Fair Value | The derivative warrant liabilities are measured at fair value at each reporting period and the reconciliation of changes in fair value is presented in the following table:
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Fair Value Assumptions | The
warrant liability was determined based on the fair value of warrants at the
issue date and the reporting dates using the Black-Scholes model with the
following weighted-average assumptions will expire on the earlier of (i) the
60th day after the date of the acceptance by the FDA of a NDA for the Company's
product candidate GTx-104 and (ii) five years from the date on issuance.
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||